Comparative Pharmacology
Head-to-head clinical analysis: FML versus IHEEZO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FML versus IHEEZO.
FML vs IHEEZO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, leading to inhibition of phospholipase A2 via annexin-1 induction, reducing prostaglandin and leukotriene synthesis; also suppresses cytokine production and inflammatory cell migration.
Iheezo (phentolamine ophthalmic solution) is an alpha-adrenergic antagonist that inhibits sympathetic tone to the iris dilator muscle, preventing mydriasis and facilitating pupil constriction during ocular surgery.
Fluorometholone ophthalmic suspension 0.1%: Instill 1 drop into conjunctival sac 2-4 times daily. In severe conditions, may increase to 1 drop every hour initially.
1 drop in the affected eye(s) 3 times daily as needed for relief of ocular discomfort. For optimal use, administer at least 10 minutes apart from other ophthalmic medications.
None Documented
None Documented
The terminal elimination half-life of fluorometholone is approximately 1.5 hours in plasma. Clinically, this short half-life allows for multiple daily dosing; however, ocular administration results in sustained local effects due to corneal binding.
The terminal elimination half-life of proparacaine is approximately 1-2 minutes due to rapid hydrolysis by plasma esterases, resulting in a very short duration of systemic exposure.
FML (fluorometholone) is primarily metabolized in the liver, with metabolites excreted renally. Approximately 70-80% of the dose is eliminated in urine as metabolites, with less than 5% as unchanged drug. Fecal excretion accounts for about 10%.
IHEEZO (proparacaine) is predominantly metabolized by plasma esterases; less than 5% is excreted unchanged in urine. Biliary/fecal elimination is negligible.
Category C
Category C
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid